DE

418.13

-6.51%↓

FDX

209.86

-2.63%↓

PAYX

143.22

-6.79%↓

CPRT

54.49

-3.76%↓

HEICA

190.52

-6.49%↓

DE

418.13

-6.51%↓

FDX

209.86

-2.63%↓

PAYX

143.22

-6.79%↓

CPRT

54.49

-3.76%↓

HEICA

190.52

-6.49%↓

DE

418.13

-6.51%↓

FDX

209.86

-2.63%↓

PAYX

143.22

-6.79%↓

CPRT

54.49

-3.76%↓

HEICA

190.52

-6.49%↓

DE

418.13

-6.51%↓

FDX

209.86

-2.63%↓

PAYX

143.22

-6.79%↓

CPRT

54.49

-3.76%↓

HEICA

190.52

-6.49%↓

DE

418.13

-6.51%↓

FDX

209.86

-2.63%↓

PAYX

143.22

-6.79%↓

CPRT

54.49

-3.76%↓

HEICA

190.52

-6.49%↓

Search

Ocugen Inc

Chiusa

0.65 1.56

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.65

Massimo

0.67

Metriche Chiave

By Trading Economics

Entrata

-910K

-14M

Vendite

-372K

764K

EPS

-0.05

Margine di Profitto

-1,816.754

Dipendenti

95

EBITDA

-603K

-13M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+910.61% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

57M

233M

Apertura precedente

-0.91

Chiusura precedente

0.65

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Ocugen Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 apr 2024, 14:32 UTC

I principali Market Mover

Ocugen Gets FDA Clearance for IND Amendment for OCU400

Confronto tra pari

Modifica del prezzo

Ocugen Inc Previsione

Obiettivo di Prezzo

By TipRanks

910.61% in crescita

Previsioni per 12 mesi

Media 6.67 USD  910.61%

Alto 8 USD

Basso 4 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Ocugen Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

3

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

0.6374 / 0.7995Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

No Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.